{"id":"insulin-lispro-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":{"setId":"c5a056e2-b568-4ca6-9ed8-79c010942d00","title":"LYUMJEV (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV JUNIOR KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV TEMPO PEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION [ELI LILLY AND COMPANY]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin lispro is a recombinant human insulin analog with a modified amino acid sequence that allows faster absorption and onset of action compared to regular human insulin. It binds to the insulin receptor on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting anabolic metabolism. This rapid action makes it particularly useful for mealtime glucose control in diabetes management.","oneSentence":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:09:37.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06948760","phase":"NA","title":"Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D","status":"COMPLETED","sponsor":"Mark D. DeBoer, MD, MSc., MCR","startDate":"2025-07-23","conditions":"Type 1 Diabetes","enrollment":11},{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT04149262","phase":"","title":"Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-15","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT06945406","phase":"PHASE1","title":"A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-16","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":124},{"nctId":"NCT07165652","phase":"PHASE1","title":"Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®","status":"COMPLETED","sponsor":"Xentria, Inc.","startDate":"2025-10-13","conditions":"Healthy Male Adult Volunteers","enrollment":54},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT05508061","phase":"NA","title":"Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Inreda Diabetic B.V.","startDate":"2022-10-19","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT06280703","phase":"PHASE1","title":"A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-15","conditions":"Healthy, Type 1 Diabetes Mellitus","enrollment":118},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT05834868","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-05-06","conditions":"Type 2 Diabetes","enrollment":1040},{"nctId":"NCT07282054","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-04-13","conditions":"Type 1 Diabetes","enrollment":550},{"nctId":"NCT07090824","phase":"PHASE1","title":"Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-10-28","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT07171684","phase":"NA","title":"Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-11-26","conditions":"Diabetes in Pregnancy, Gestational Diabetes","enrollment":176},{"nctId":"NCT04124302","phase":"PHASE4","title":"The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2019-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":76},{"nctId":"NCT05893797","phase":"NA","title":"A Study of LY8888AX in Participants Using a Connected Insulin Management Platform","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-10-05","conditions":"Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":36},{"nctId":"NCT06370715","phase":"PHASE4","title":"A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-04-18","conditions":"Diabetes Mellitus, Type 2","enrollment":150},{"nctId":"NCT03903016","phase":"PHASE1","title":"A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-26","conditions":"Type 1 Diabetes","enrollment":90},{"nctId":"NCT02293551","phase":"PHASE1","title":"A Study of Lispro Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT06238778","phase":"PHASE2","title":"Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diasome Pharmaceuticlas, Inc.","startDate":"2024-01-23","conditions":"Diabetes Mellitus, Type 1","enrollment":227},{"nctId":"NCT07109245","phase":"PHASE4","title":"Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?","status":"NOT_YET_RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2025-09-01","conditions":"Brain Insulin Sensitivity, Healthy Controls, Cognition","enrollment":35},{"nctId":"NCT05748990","phase":"NA","title":"Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-04-01","conditions":"Schizophrenia, Healthy","enrollment":20},{"nctId":"NCT05463744","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-12","conditions":"Type 1 Diabetes, Diabetes","enrollment":692},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT05462756","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-11","conditions":"Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":730},{"nctId":"NCT06931041","phase":"PHASE3","title":"Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2024-02-01","conditions":"Dry Eye, Sjogren Syndrome","enrollment":25},{"nctId":"NCT05571878","phase":"NA","title":"Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2021-09-01","conditions":"Major Depressive Disorder, Depression","enrollment":24},{"nctId":"NCT04200313","phase":"NA","title":"The Insulin-Only Bionic Pancreas Pivotal Trial","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2020-03-31","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1","enrollment":440},{"nctId":"NCT05325294","phase":"NA","title":"Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2022-05-05","conditions":"Type 1 Diabetes","enrollment":244},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT05218915","phase":"PHASE4","title":"Basal Plus GLP1-ra on Glycemic Variability in CKD","status":"COMPLETED","sponsor":"Elaine Chow","startDate":"2022-01-28","conditions":"Diabetes Mellitus, Diabetic Kidney Disease","enrollment":95},{"nctId":"NCT06419803","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT06419777","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT05689424","phase":"PHASE1","title":"Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-02-01","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT06600776","phase":"PHASE4","title":"Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System","status":"NOT_YET_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-10-06","conditions":"Type 1 Diabetes (T1D)","enrollment":50},{"nctId":"NCT05262387","phase":"PHASE1","title":"A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-02-14","conditions":"Diabetes Mellitus, Type 1","enrollment":25},{"nctId":"NCT06532461","phase":"NA","title":"A Trial of Three- and Seven-days Insulin Infusions Set","status":"RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2024-07-20","conditions":"Type 1 Diabetes","enrollment":80},{"nctId":"NCT06251635","phase":"NA","title":"Effects of Antipsychotics on Brain Insulin Action in Females","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-06-03","conditions":"Insulin Resistance, Menstrual Cycle, Type 2 Diabetes","enrollment":15},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT06346366","phase":"PHASE3","title":"Glucose Control Through a Bihormonal Artificial Pancreas in Patients After Total Pancreatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-04-25","conditions":"Pancreatic Neoplasms, Type 3c Diabetes, Total Pancreatectomy","enrollment":40},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT03660553","phase":"PHASE4","title":"Simplified Insulin Regimen for the Elderly","status":"TERMINATED","sponsor":"University of Miami","startDate":"2018-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":7},{"nctId":"NCT06153329","phase":"PHASE1","title":"A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2021-06-17","conditions":"Healthy","enrollment":39},{"nctId":"NCT04019821","phase":"PHASE4","title":"Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2020-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":72},{"nctId":"NCT04537923","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-19","conditions":"Type 2 Diabetes","enrollment":1428},{"nctId":"NCT05457933","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-07-29","conditions":"Type2diabetes, Coronary Artery Disease","enrollment":250},{"nctId":"NCT05373186","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Healthy","enrollment":27},{"nctId":"NCT05067270","phase":"PHASE1","title":"A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-10-22","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT05579119","phase":"PHASE4","title":"SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)","status":"COMPLETED","sponsor":"Hospital de Especialidades, Centro Medico Nacional \"La Raza\", Instituto Mexicano del Seguro Social","startDate":"2022-07-06","conditions":"Type 2 Diabetes","enrollment":76},{"nctId":"NCT05373199","phase":"PHASE1","title":"A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT05543850","phase":"NA","title":"Portable Artificial Pancreas Applied for Youth and Adolescents","status":"COMPLETED","sponsor":"Inreda Diabetic B.V.","startDate":"2022-10-28","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT05726461","phase":"NA","title":"Efficacy and Safety of Android Artificial Pancreas System in Adult Patients With Type 1 Diabetes Mellitus in China","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-02-11","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders","enrollment":25},{"nctId":"NCT03741478","phase":"PHASE1","title":"Intranasal Insulin and Olanzapine Study in Healthy Volunteers","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-10-22","conditions":"Healthy Controls","enrollment":64},{"nctId":"NCT05257460","phase":"NA","title":"Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_Phase 4)","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2022-01-25","conditions":"Type 1 Diabetes","enrollment":28},{"nctId":"NCT04243629","phase":"NA","title":"Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes","status":"UNKNOWN","sponsor":"McGill University","startDate":"2021-11-12","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia","enrollment":26},{"nctId":"NCT03952130","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-29","conditions":"Type 1 Diabetes Mellitus","enrollment":354},{"nctId":"NCT04079881","phase":"PHASE1, PHASE2","title":"Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-02-13","conditions":"Type 1 Diabetes, Hyperglycemia, Postprandial","enrollment":1},{"nctId":"NCT04816890","phase":"PHASE2","title":"A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"Adocia","startDate":"2021-03-23","conditions":"Type 1 Diabetes Mellitus","enrollment":80},{"nctId":"NCT01613807","phase":"PHASE4","title":"Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-10","conditions":"Gestational Diabetes Mellitus","enrollment":40},{"nctId":"NCT03234491","phase":"PHASE1","title":"Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-11-22","conditions":"Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia","enrollment":15},{"nctId":"NCT03260868","phase":"PHASE4","title":"Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-19","conditions":"Type 1 Diabetes Mellitus","enrollment":15},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT03547427","phase":"NA","title":"Glucagon Counterregulation in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-05-20","conditions":"Type 1 Diabetes Mellitus","enrollment":13},{"nctId":"NCT04783376","phase":"PHASE4","title":"Effect of Splitting Mealtime Insulin Doses After Mixed Meals High in Fat and Protein","status":"COMPLETED","sponsor":"Sohag University","startDate":"2021-04-12","conditions":"Type 1 Diabetes Mellitus","enrollment":43},{"nctId":"NCT02227862","phase":"PHASE3","title":"Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-06","conditions":"Type 1 Diabetes","enrollment":558},{"nctId":"NCT02666430","phase":"PHASE3","title":"Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-12","conditions":"Type 1 Diabetes Mellitus","enrollment":127},{"nctId":"NCT04972175","phase":"PHASE1","title":"Safety and Efficacy of BC LisPram","status":"UNKNOWN","sponsor":"Michael Tsoukas","startDate":"2021-07-28","conditions":"Type1 Diabetes Mellitus","enrollment":16},{"nctId":"NCT03952143","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-27","conditions":"Type 2 Diabetes Mellitus","enrollment":628},{"nctId":"NCT04031599","phase":"NA","title":"Assessment of the Efficacy of the Artificial Pancreas Combined With a Qualitative Meal Size Estimation to Control Postprandial Glucose Levels","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2020-07-10","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT03350984","phase":"PHASE4","title":"Insulin Schemes for Type 2 Diabetes Control","status":"COMPLETED","sponsor":"Universidad de Guanajuato","startDate":"2017-11-02","conditions":"Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT04049123","phase":"PHASE1","title":"A Study of LY900014 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-11-18","conditions":"Healthy","enrollment":15},{"nctId":"NCT04157738","phase":"PHASE4","title":"A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-27","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":24},{"nctId":"NCT04276207","phase":"PHASE1","title":"A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-25","conditions":"Diabetes Mellitus, Type 1","enrollment":32},{"nctId":"NCT01269034","phase":"PHASE4","title":"New Onset Type 1 Diabetes: Role of Exenatide","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2010-12","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT04965051","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08","conditions":"Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range","enrollment":40},{"nctId":"NCT03338023","phase":"PHASE3","title":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-23","conditions":"Type 1 Diabetes","enrollment":272},{"nctId":"NCT02971228","phase":"PHASE2","title":"Feasibility Trial Testing the Bionic Pancreas With ZP4207","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2016-11","conditions":"Diabetes Mellitus, Type 1","enrollment":13},{"nctId":"NCT02432976","phase":"PHASE2, PHASE3","title":"Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2015-05","conditions":"Quality of Life","enrollment":64},{"nctId":"NCT04739241","phase":"PHASE4","title":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Consorci Sanitari Integral","startDate":"2014-01-24","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":60},{"nctId":"NCT03830281","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-14","conditions":"Type 1 Diabetes Mellitus","enrollment":471},{"nctId":"NCT00461331","phase":"PHASE4","title":"Comparison of Insulins Aspart and Lispro in Insulin Pumps","status":"COMPLETED","sponsor":"Tulane University Health Sciences Center","startDate":"2004-10","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT04484779","phase":"NA","title":"A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-14","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":67},{"nctId":"NCT04501107","phase":"PHASE1","title":"A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2020-08-03","conditions":"Type 1 Diabetes","enrollment":32},{"nctId":"NCT02229227","phase":"PHASE3","title":"Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-21","conditions":"Diabetes Mellitus, Type 2","enrollment":814},{"nctId":"NCT03760640","phase":"PHASE2","title":"A Study of LY900014 in a Medtronic Pump","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-18","conditions":"Type1 Diabetes Mellitus","enrollment":42},{"nctId":"NCT02192424","phase":"PHASE3","title":"Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":109},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT04161976","phase":"PHASE1","title":"A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-27","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT02206568","phase":"PHASE1","title":"Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT03465878","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-26","conditions":"Type 1 Diabetes Mellitus","enrollment":56},{"nctId":"NCT02703337","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT02703324","phase":"PHASE1","title":"A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT02703350","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT02846831","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-01-24","conditions":"Type 1 Diabetes","enrollment":36},{"nctId":"NCT03341312","phase":"PHASE1","title":"A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-13","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT02770521","phase":"PHASE1","title":"A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05","conditions":"Healthy","enrollment":23},{"nctId":"NCT03305822","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":38},{"nctId":"NCT02525744","phase":"PHASE1","title":"A Study of a New LY900014 Formulation in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT03341299","phase":"PHASE1","title":"A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-13","conditions":"Diabetes Mellitus, Type 1","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY275585"],"phase":"marketed","status":"active","brandName":"Insulin lispro A","genericName":"Insulin lispro A","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for energy and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}